STATEMENT RE BIOCRYST.

1 July 2025

BIOPHARMA CREDIT PLC

(THE "COMPANY")

STATEMENT RE BIOCRYST

Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released on 27 June 2025 by BioCryst Pharmaceuticals, Inc. ("BioCryst") regarding entering into a definitive agreement to sell its European ORLADEYO® (berotralsat) business to Neopharmed Gentili for up to US$264 million (the "Transaction"). BioCryst expects to close the sale by early October and plans to use the proceeds from the Transaction to retire all remaining term debt of US$248.7 million existing under the existing loan agreement with its lenders, including US$99.5 million owed to the Company.

Pursuant to the senior secured loan agreement, in connection with the Transaction and the repayment of outstanding principal, the Company is expected to receive a prepayment premium of 3 per cent. with respect to the principal repaid. For illustrative purposes, if the Transaction were to close on 1 October 2025, the Company would be expected to receive approximately US$3 million in prepayment fees.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.